Memantine is the currently available NMDA receptor antagonist to normalize the glutamatergic system and ameliorate cognitive and memory deficits in AD.6 The cleavage of amyloid beta (Aβ) from the amyloid precursor protein (APP) by the beta site amyloid precursor protein cleaving enzyme (BACE 1), also known as beta secretase, plays a role in the pathogenesis of AD.7 As the inhibitors NMDA receptor and BACE1 are associated with reduction in glutamate and amyloid beta toxicity, respectively. Here, BACE1 is linked to Alzheimer disease.